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Introduction 8 
Fibroadenomas account for approximately 40% of breast biopsies performed around the world (1-3). 9 
The performance of these biopsies, pathological processing, pathological interpretation and 10 
discussion of the results is a large part of the workload of breast clinics. 11 
The different ultrasound (US) features of breast cancer and fibroadenomas are well known (4,5) and 12 
the sensitivity of US for the detection of breast cancer is around 95%. Studies have shown that the 13 
sensitivity and specificity of ultrasound is statistically significantly greater than mammography in 14 
patients with breast symptoms for the detection of breast cancer and benign lesions particularly in 15 
dense breast and in young women (6). However, US of triple-negative (TN) cancers poses a particular 16 
problem as they often show benign US features such as distal enhancement and a well-defined 17 
margin (7.8). This problem is compounded by the young age distribution of TN breast cancer, which 18 
likely means that the pre-test probability of malignancy is relatively low. However, given the very 19 
low cancer incidence in women under 25 years old, many centres are now routinely using US 20 
features alone to determine when breast masses are benign (9,10). Some centres have also 21 
increased this age threshold to 30 years. 22 
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Shear wave elastography (SWE) is an US technique which measures tissue stiffness quantitatively 23 
and reproducibly. It has a similar sensitivity for invasive breast cancer as greyscale US (11). It takes 24 
about two minutes to perform and two minutes to extract the quantitative readings per case. The 25 
small proportion of cancers with benign SWE values tend to be small, screen-detected and low-grade 26 
(12). Such cancers are, however, rarely missed or misclassified by greyscale US. This means that SWE 27 
and greyscale US are complementary when used in combination to assess breast masses, with 28 
greyscale US missing some high-grade lesions and SWE some low-grade cancers. This is especially 29 
true when assessing women with symptoms, where small, low-grade cancers are less common. In a 30 
series of almost 700 symptomatic solid lumps, none of the cancers showed both benign greyscale US 31 
features and benign SWE features (13). A particular advantage of SWE is that its sensitivity for the 32 
detection of lobular cancer is similar to that for ductal (no-special-type) cancers (14). This is in 33 
contrast to all other routine breast imaging modalities.  34 
Because of the above studies, our centre adopted a policy of not biopsying or following up 35 
symptomatic, clinically benign masses with benign greyscale US and SWE findings in women under 36 
40 years of age. This policy was adopted in 2017. The aim of this study was to assess the outcomes 37 
of this policy in women aged 25-39 years, where a minimum of 12 months’ follow-up data is 38 
available.  39 
Methods 40 
Patients were included after attending a one-stop clinic for women referred from their family doctor 41 
with breast symptoms. All patients complaining of a breast lump routinely have a focussed breast 42 
ultrasound scan with SWE examination of any solid mass seen on ultrasound. Four SWE images are 43 
obtained in two orthogonal planes and quantitative data obtained using a 2mm region of interest 44 
(ROI). Patients aged 25-39 with lesions showing benign US and clinical features and SWE findings 45 
below the threshold value (50 kPa average mean stiffness from the four SWE images) were 46 
reassured and discharged from the clinic without biopsy or follow-up. Mammography was not 47 
3 
 
performed as the patients were under 40 years and did not have suspicious clinical or US findings. 48 
Patients managed in this way had their details recorded on a dedicated audit form for review by a 49 
second radiologist. The single reviewing radiologist, an internationally recognised expert with 25 50 
years specialist experience in breast imaging, checked that the lesion did have definitively benign US 51 
features. If the second radiologist did not agree with the benign US designation, the patient was 52 
recalled for repeat US and possible core biopsy.  53 
Patients managed in this way before 01/05/2019 were included in this audit. Local electronic records 54 
were viewed to establish whether patients re-presented with the same or different benign breast 55 
problems, developed breast cancer, or had further diagnostic biopsies. If local records did not show 56 
recent attendance, then the national picture archiving and communication system (PACS) was 57 
accessed to identify any subsequent breast imaging anywhere in the NHS in the devolved UK nation 58 
that was the setting for this study. 59 
Rates of recall and re-assessment review of stored US images by the second radiologist were 60 
documented. Similarly, rates of re-presentation with the same benign lesion, other benign problems 61 
and breast cancer were calculated.  62 
Results 63 
Seventy-six consecutive patients were eligible for the audit. The age range was 25-39 years with a 64 
mean age of 33 years. The minimum follow-up was 12 months. Average follow-up was 2 years. One 65 
patient was excluded as she died of non-breast causes two weeks after attending the clinic, leaving 66 
75 women in the cohort. 67 
Three (4%) patients were recalled after review of the US images by the second radiologist. Two were 68 
discharged following a second US scan while one underwent a core biopsy with a benign result. Five 69 
(7%) patients re-presented with the same lump, two of those had a core biopsy at this second 70 
presentation because of enlargement of the lesion, with benign results. Three women had a similar 71 
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sized lump as at initial presentation and were further reassured and discharged. None of the five 72 
patients who re-presented had a surgical excision of the lump. Three (4%) patients presented with a 73 
different benign problem during follow-up.  74 
Two patients presented with breast cancer, both in the ipsilateral breast. In neither patient was the 75 
cancer in the same area as the previously assessed benign lump. In both cases, imaging including 76 
MRI scan confirmed the cancers as separate from the previously assessed benign lesions. 77 
None of the women in the study cohort presented to other NHS breast units in the country and had 78 
breast imaging recorded on PACS during the follow-up period.  79 
The number of women aged 25-39 who had symptomatic clinically benign masses with benign core 80 
biopsy results who were biopsied because of atypical US appearances or stiffness at SWE was not 81 
recorded.  82 
Discussion 83 
We have found that a policy of not biopsying or following up symptomatic, clinically benign solid 84 
breast masses with benign US and SWE features appears safe so far, as no cancers were diagnosed 85 
at follow-up in the area of the previously assessed benign masses. There was good consensus among 86 
the radiologists regarding the benign US findings as only 4% were recalled for reassessment after 87 
review of the stored US images by the second radiologist, and all such reassessments had a benign 88 
outcome. Only 7% of patients re-presented with the same lump and these episodes resulted in two 89 
core biopsies but no surgical excisions. The lack of surgical excisions may imply that the patients on 90 
the new pathway were adequately reassured. 91 
The number of women aged 25-39 years who had their clinically benign masses biopsied during the 92 
study period because of either non-benign US greyscale features or above-threshold stiffness at SWE 93 
was not recorded. It is therefore not possible to say what percentage of women with benign 94 
symptomatic masses in this age group avoided core biopsy due to adoption of this policy.  95 
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It is estimated that 10% of all women have a fibroadenoma (15) and that about 40% of breast 96 
biopsies are from fibroadenomas (1-3). The burden of work caused by fibroadenomas is therefore 97 
difficult to overstate. Given the greater and increasing complexity of radiological workup of cancer 98 
cases, any decrease in work from benign problems will enable breast radiologists to give more time 99 
to imaging of cancer cases.  100 
The follow-up of an average of two years in this study is short and it is possible that missed cancers 101 
may yet appear. Therefore, these results can only be interpreted as promising rather than as 102 
definitive evidence of the safety of this approach. However, most re-presentations of an 103 
undiagnosed but already symptomatic cancer occur within two years (16). Only 7% of cancers 104 
occurring as “interval cancers” after assessment at one-stop symptomatic clinics occur in women 105 
aged under 40; therefore, reducing diagnostic interventions in this age group would appear not be a 106 
high-risk strategy (16).  107 
A further limitation of this study is that it is a small sample from a single centre with an academic 108 
interest in SWE. However, SWE is a simple, reproducible technique so it would be surprising if these 109 
results could not be replicated by other centres. SWE is also a quick, relatively low-cost procedure, 110 
so its introduction into the standard workflow of any breast clinic should not present problems.  111 
The adoption of this approach by other centres is only recommended after individual centres assess 112 
a cohort of patients to confirm that no cancers are missed by both SWE and US, while continuing to 113 
biopsy clinically benign masses with benign US and SWE features in the age-group concerned. The 114 
majority of cancers missed by SWE are small (11), so some may wish to adopt this approach for 115 
lesions over 10mm in size only.  116 
As follow-up and biopsy of benign masses constitutes a large part of breast radiologists’ workload, in 117 
health care systems where a fee-per-item model exists there may be concerns about resultant 118 
decrease in income.  119 
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Extending the age limit for this policy to 49 years could be contemplated after longer follow-up of a 120 
larger numbers of patients. However, it should be noted that women aged 40-49 are those most 121 
likely to have a cancer presenting following a one stop clinic negative assessment (15) so such an 122 
approach should be considered cautiously.  123 
In conclusion, early results of a policy of not biopsying or following up benign solid masses with 124 
benign US appearances, which are soft on SWE, in women aged 25-39 suggest this approach may be 125 
safe and acceptable. Data on larger cohorts from multiple centres with longer follow-up are required 126 
to confirm this early promise.  127 
 128 
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